<DOC>
	<DOC>NCT03081546</DOC>
	<brief_summary>This study plans to assess the effectiveness of performance-based functional assessments (PBFAs) and cognitive assessments in diagnosing Alzheimer's disease in Hispanic/Latino populations. The information from this study will be analyzed with data from the Rocky Mountain Alzheimer's Disease Center Bio-AD study (NCT02612376).</brief_summary>
	<brief_title>Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Persons with agerelated MCI or AD according to clinical diagnosis, consistent with National Institute on AgingAlzheimer's Association (NIAAA) diagnostic criteria Communitydwelling controls Age &gt; 55 years Have been enrolled and completed at least one visit in the BioAD study and consent to access their data (the Rocky Mountain Alzheimer's Disease Center BioAD study (clinicaltrials.gov identifier: NCT02612376)) Have capacity to provide consent; capacity will be assessed at the time of consent Ability to complete baseline assessments Has informant (study partner) available to complete functional interviews/survey measures Presence of concomitant medical, neurological, or psychiatric illness or condition that in the opinion of the investigators would confound interpretation of study results. These include: Korsakoff encephalopathy; active substance abuse; hepatitis C; opportunistic brain infection; brain tumor; active neoplastic disease (skin tumors other than melanoma are not exclusionary; participants with stable prostate cancer may be included at the discretion of the project director); multiple sclerosis; history of clinically significant stroke; current evidence or history in the past 2 years of focal brain lesion, head injury with loss of consciousness in the past year, or DSM5 criteria for any major psychiatric disorder, including 1. psychosis, 2. uncontrolled major depression, 3. bipolar disorder, 4. alcohol or substance abuse; 5. blindness, 6. deafness or 7. any other disability which may prevent the participant from participating or cooperating in the protocol. Prisoners Any contraindication for MRI</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>